Natalizumab Completed Phase 4 Trials for Disseminated Sclerosis Diagnostic

IndicationsStatusPurposePhase
CompletedDiagnostic4
clinicaltrials.gov IdentifierTitleDrugs
NCT00942214Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment